Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study

Lancet

Volumn 358, Issue 9283, 2001, Pages 718-723

  Benhamou, Y ^a,b   Bochet, M ^a,b   Thibault, V ^a   Calvez, V ^a   Fievet, M H ^a   Vig, P ^c   Gibbs, C S ^c   Brosgart, C ^c   Fry, J ^c   Namini, H ^c   Katlama, C ^a   Poynard, T ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CNRS   (France)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACICLOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; HEPATITIS B(E) ANTIGEN; INDINAVIR; INSULIN; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS DNA; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MALE; NEPHROTOXICITY; PATIENT; PILOT STUDY; PRIORITY JOURNAL; SEROCONVERSION; SUPERINFECTION;

EID: 0035449134     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)05840-8     Document Type: Article

References (30)

1. Progress on the control of hepatitis B infection through immunisation
2. Hepatitis B infection in the acquired immunodeficiency syndrome
3. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men
4. A one year trial of lamivudine for chronic hepatitis B
5. A preliminary trial of lamivudine for chronic hepatitis B infection
6. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men
7. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
8. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
9. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus
10. Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance
11. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
12. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment
13. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients
14. Two year lamivudine therapy in chronic hepatitis B infection: Results of a placebo-controlled multicentre study in Asia
15. Three year lamivudine therapy in chronic HBV
16. Incremental increases in HBeAg seroconversion and continued alanine aminotransferase normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years
17. Post liver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: Long-term follow-up
18. In vitro characterization of the anti-human cytomegalovirus activity of PMEA (adefovir)
19. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
20. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl) adenine, an acyclic phosphonate nucleoside analogue
21. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance
22. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection
23. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: Two placebo-controlled phase II studies
24. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
25. Second worldwide evaluation of HIV-1 drug resistance genotyping quality using the ENVA 2 panel
26. Resistance table mutations in retroviral genes associated with drug resistance: 2000-2001 update
27. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C
28. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation
29. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized, controlled trial
30. Glucose disorder associated with HIV and its drug therapy